CareDx (CDNA) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
11 Jun, 2026Opening remarks and agenda
The meeting was called to order by the CEO, who introduced the board, legal counsel, and the independent auditor, and outlined the virtual meeting procedures.
The agenda included five items: election of directors, ratification of the auditor, advisory votes on executive compensation and its frequency, and an amendment to the equity incentive plan.
Board and executive committee updates
Five current directors were nominated for re-election to serve until the 2027 annual meeting or until successors are elected.
Shareholder proposals
No shareholder proposals or director nominations were received in advance of the meeting.
Partial view of Summaries dataset, powered by Quartr API
Latest events from CareDx
- Precision diagnostics focus, Naveris acquisition, and pipeline expansion drive growth and profitability.CDNA
Goldman Sachs 47th Annual Global Healthcare Conference 20268 Jun 2026 - Stockholders to vote on 2025 executive compensation, with clarified bonus calculation methods.CDNA
Proxy filing5 Jun 2026 - Q1 revenue up 39%, pipeline expands with Naveris and AlloHeme, driving future growth.CDNA
Jefferies Global Healthcare Conference 20263 Jun 2026 - Q1 2026 revenue up 39% to $118M, net income positive, guidance raised, and major M&A moves.CDNA
Q1 202629 Apr 2026 - Key votes include director elections, auditor ratification, and expanding the equity incentive plan.CDNA
Proxy filing28 Apr 2026 - Key votes include director elections, auditor ratification, and executive pay at the 2026 meeting.CDNA
Proxy filing27 Apr 2026 - AlloHeme enables highly sensitive, non-invasive relapse detection in AML/MDS post-HCT, launching in 2027.CDNA
Status update13 Apr 2026 - Strong growth, innovation, and market expansion drive leadership in transplant diagnostics.CDNA
47th Annual Raymond James Institutional Investor Conference3 Mar 2026 - 2025 revenue up 14% to $380M; 2026 guidance $420–$444M with strong growth and innovation.CDNA
Q4 202525 Feb 2026